ProQR Therapeutics NV expected to post a loss of 25  cents a share - Earnings Preview

ProQR Therapeutics NV

03/05/2021 14:27

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected to show
a rise in quarterly revenue when it reports results on May 5
(estimated).
* The Leiden, Zuid-holland-based company is expected to report
 a 115.9% increase in revenue to €567.78 thousand from €263
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.​​
​* Refinitiv's mean analyst estimate for ProQR Therapeutics NV
is for a loss of 25 cents per share. For the same quarter last
year, the company reported a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months.​
* Wall Street's median 12-month price target for ProQR
Therapeutics NV is $23​, about 73% above​ its last closing price
of $6.22. ​​​
* Previous quarterly performance (using preferred earnings
measure in euros). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.25       -0.25      -0.26     Missed  -3.6
 Sep. 30 2020  -0.30       -0.30      -0.26     Beat    13.5
 Jun. 30 2020  -0.29       -0.33      -0.08     Beat    75.6​
 Mar. 31 2020  -0.34       -0.34      -0.32     Beat    6.4
 Dec.          -0.35​      -0.35      -0.39     Missed  -10.6​
 31​ 2019​                                              
 Sep. 30 2019  -0.33       -0.34      -0.31     Beat    9.9​
 Jun. 30 2019  -0.38       -0.38      -0.32     Beat    16.5
 Mar. 31 2019  -0.37       -0.36      -0.40     Met     1
 This summary was machine generated May 3 at 13:27 GMT.  All
figures in euros unless otherwise stated